Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect

Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect

Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or tr...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics Vol. 13; no. 4; p. 570
Main Authors: Frickenstein, Alex N, Hagood, Jordan M, Britten, Collin N, Abbott, Brandon S, McNally, Molly W, Vopat, Catherine A, Patterson, Eian G, MacCuaig, William M, Jain, Ajay, Walters, Keisha B, McNally, Lacey R
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 17-04-2021
MDPI
Subjects:
active targeting
cancer
Ligands
mesoporous silica
nanomedicine
Nanoparticles
Physiology
Proteins
Review
Silica
Surfactants
theragnostics
theranostics
toxicity
controlled release
mesoporous silica
theragnostics
nanomedicine
theranostics
cancer
active targeting
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13040570